Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.

Chemistry

The drug is a peptide with amino acid sequence 

YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³

where superscript numbers refer to unique chemical modifications:

  1. "A¹" refers to 2-aminoisobutyric acid (AiB) instead of alanine.
  2. "L²" refers to alpha-methyl added to leucine (MeL, 2-methylleucine).
  3. "S³" refers to addition of an amino group to the C-terminal serine.
  4. "K⁴" refers to a modification group attached to the lysine's tail amine, specifically (AEEA)-gamma-Glu-C20 diacid.

References


Retatrutide A New Weight Loss High.pptx

Buy Retatrutide (LY3437943) Triple Agonist Peptide for weight loss

Retatrutide (Weight Loss)

Navigating the Weight Loss Maze Retatrutide vs. Tirzepatide Better

Retatrutide for weight loss Diabetes UK